“OncoOne has had a successful start to 2023, with the lead oxMIF mAb for solid tumors, ON203, being featured in the American Association for Cancer Research’s journal Molecular Cancer Therapeutics. The summary of ON203’s design and preclinical experiments has been published online in conjunction with the AACR Annual Meeting 2023 in Orlando and will be MCT’s feature article in May. Congrats to the team for this achievement! The OncoOne team’s efforts were also recognized with a presentation of the fourth preclinical data set from our lead immunology oxMIF mAb, ON104, at the European Crohn’s and Colitis Organisation’s March meeting in Copenhagen. Thus far, we have demonstrated the efficacy of ON104 in mouse models of glomerulonephritis, rheumatoid arthritis, and two models of colitis. Furthermore, our PreTargit® program also received a great deal of attention at AACR 2023, showcasing impressive preclinical proof-of-concept data. We are excited to attend upcoming events such as Asia Bio Partnering Forum in Singapore, Bio Equity Europe in Dublin, and the IMMUNOLOGY 2023™ AAI Annual Meeting in Washington, DC in May, where we will be presenting exciting new data.” Randolf Kerschbaumer, CEO OncoOne